Results 171 to 180 of about 56,276 (247)

Case Report: Serum sickness induced by dupilumab-clinical insights and Olinkproteomic analysis. [PDF]

Front Immunol
Zhu H, Huang Q, Zheng L, Yao W, Xia J.
europepmc   +1 more source

Biologically targeted dual adaptive and innate nano-Immunotherapy for clear cell renal cell carcinoma treatment. [PDF]

Mol Cancer
Au KM, Li S, Zhang T, Wang AZ.
europepmc   +1 more source

CLDN18.2 CAR‐derived Extracellular Vesicle Immunotherapy Improves Outcome in Murine Pancreatic Cancer

Advanced Healthcare Materials, Volume 14, Issue 16, 23 June, 2025.
CLDN18.2 CAR‐T cell‐derived small extracellular vesicles (CAR‐sEVs) display potent cytotoxicity and prolong survival in preclinical pancreatic cancer models. They contain functional CAR proteins and granzyme B, exhibit antigen specificity, and effectively target tumor cells while sparing healthy cells.
Yue Qing, Ke Jiang, Hua Jiang, Yaru Zhao, Chu‐Hu Lai, Alexandra Aicher, Zonghai Li, Christopher Heeschen   +7 more
wiley   +1 more source

Design of a humanized CD40 agonist antibody with specific properties using AlphaFold2 and development of an anti-PD-L1/CD40 bispecific antibody for cancer immunotherapy. [PDF]

Transl Oncol
Du K, Huang H.
europepmc   +1 more source

Engineering CAR‐T Therapeutics for Enhanced Solid Tumor Targeting

Advanced Materials, Volume 37, Issue 23, June 12, 2025.
CART cell therapy has proven effective for blood cancers but struggles with solid tumors due to diverse antigens and complex environments. Recent efforts focus on improving CAR design and validation platforms. Advances in protein engineering, machine learning, and organoid systems aim to enhance CAR‐T therapy against solid tumors.
Danqing Zhu, Won Joon Kim, Hyunjin Lee, Xiaoping Bao, Pilnam Kim   +4 more
wiley   +1 more source

Dual biological treatments in immune-mediated disorders: a single center experience. [PDF]

BMC Immunol
Shamriz O, Parnasa E, Rubin L, Talmon A, Ribak Y, Hindi I, Peleg H, Confino-Cohen R, Tal Y.   +8 more
europepmc   +1 more source

TP53 ‐Mutated Myeloid Neoplasms: 2024 Update on Diagnosis, Risk‐Stratification, and Management

American Journal of Hematology, Volume 100, Issue S4, Page 88-115, June 2025.
ABSTRACT Alterations in the tumor suppressor gene TP53 are common in human cancers and are associated with an aggressive nature. Approximately 8%–12% of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) harbor TP53 mutations (TP53 mut) and present immense challenges due to inherent chemoresistance and poor outcomes.
Mithun Vinod Shah, Daniel A. Arber, Devendra K. Hiwase   +2 more
wiley   +1 more source

Potentiating Antibody-Dependent Cellular Cytotoxicity in Triple-Negative Breast Cancer via the Humanized Anti-CD147 Antibody. [PDF]

Antibodies (Basel)
Thongheang K, Pamonsupornwichit T, Sornsuwan K, Juntit OA, Chokepaichitkool T, Thongkum W, Yasamut U, Tayapiwatana C.   +7 more
europepmc   +1 more source

Application of humanized mice in the safety experiments of antibody drugs

Animal Models and Experimental Medicine, Volume 8, Issue 6, Page 1023-1032, June 2025.
The graphical abstract of this review highlights the critical role of humanized mice in the safety evaluation of antibody drugs. First, the inherent immunogenicity of antibody drugs can lead to the production of antidrug antibodies and hypersensitivity reactions on repeated administration.
Zhimin Sun, Mengyun Gu, Zixuan Yang, Lei Shi, Liyuan Zhao, Minhui Zheng, Yan Wang, Wei Zhang, Kexin Han, Naping Tang   +9 more
wiley   +1 more source